Active ingredient: Domperidone 10 mg
Dosage form: Film-coated tablets
Pack size: 20 tablets
Route: Oral use
Manufacturer: Viatris
Domperidone is a dopamine D2-receptor antagonist with prokinetic and antiemetic action. It accelerates gastric emptying and increases lower esophageal sphincter tone - relieving bloating, early satiety, nausea and reflux-type discomfort. Importantly, it does not cross the blood-brain barrier in significant amounts, so it lacks the sedation and extrapyramidal risks of older antiemetics like metoclopramide.
Original European product by Viatris. Prescription status varies by country - in most European countries it is a pharmacy medicine; long-term use requires medical supervision.
Standard adult dosing: 10 mg up to three times daily, taken 15-30 minutes before meals. Maximum duration without medical supervision is typically short (per approved protocols); prolonged courses require physician oversight. Tablets are swallowed whole with water, before food for the prokinetic effect.
Domperidone has a well-characterized cardiac safety profile at standard doses, but QT prolongation is possible at high doses or with interacting medicines (certain antibiotics, antifungals). Physicians assess cardiac risk before long-term courses. Common side effects: dry mouth, headache, abdominal cramps - usually mild.
Store at a temperature not exceeding 25 °C, in the original package. Keep out of reach of children.
Motilium is the original Janssen brand; Domperidone Viatris contains the same molecule at the same 10 mg strength. The Viatris version is the European generic with equivalent bioavailability.
Domperidone barely crosses the blood-brain barrier, so it does not cause the sedation and movement disorders (extrapyramidal symptoms) typical of metoclopramide. Its main safety focus is cardiac - at standard doses the risk is low.
Before meals (15-30 min): this timing maximizes the prokinetic effect on gastric emptying.
Long-term courses require physician supervision with cardiac risk assessment. Short courses (up to 1-2 weeks per protocol) are standard for functional dyspepsia.
Patients with prolactinoma, cardiac conduction disorders, those taking QT-prolonging medicines, severe liver impairment, pregnant/breastfeeding women (per physician decision).
Ask a question or inquire about delivery to your country

